Target intelligence / Profile preview

Sodium-dependent neutral amino acid transporter B0AT1 (B0AT1)

Target
B0AT1
Molecular classification
Transporter, Solute carrier
01

Overview

Sodium-dependent neutral amino acid transporter B0AT1 (encoded by the SLC6A19 gene) is the major epithelial transporter responsible for the absorption of neutral amino acids in the small intestine and their reabsorption in the proximal tubules of the kidney. It operates as a sodium-coupled symporter, co-transporting one sodium ion with one neutral amino acid across the apical membrane. B0AT1 requires accessory proteins, such as collectrin (TMEM27) in the kidney and angiotensin-converting enzyme 2 (ACE2) in the intestine, for its trafficking, surface expression, and catalytic activity.

Inhibition of B0AT1 has emerged as a promising therapeutic strategy for metabolic and genetic disorders. In phenylketonuria (PKU), blocking B0AT1 reduces the absorption and reabsorption of phenylalanine, promoting its excretion in urine and lowering toxic plasma phenylalanine levels. In chronic kidney disease (CKD), B0AT1 inhibition reduces the metabolic overload of amino acids in the proximal tubules, potentially slowing disease progression. Furthermore, B0AT1 inhibition mimics dietary protein restriction, which improves glycemic control and insulin sensitivity by upregulating beneficial metabolic hormones like FGF21 and GLP-1, offering a novel approach for treating type 2 diabetes and obesity. Investigational small-molecule inhibitors, such as JNT-517, MZE782, and GenSci144, are currently in clinical development.

Other names
System B0 neutral amino acid transporterB0AT-type amino-acid transportersSLC6A19Solute carrier family 6 member 19System B(0) neutral amino acid transporter AT1HND
02

Mechanism of action

Allosteric inhibition of the transporter, stabilizing the outward-open conformation and preventing transition to the inward-open state, thereby blocking neutral amino acid transport.

03

Biological functions

Amino acid transportSodium-dependent symportNutrient absorptionRenal reabsorption
04

Disease associations

PhenylketonuriaChronic kidney diseaseType 2 diabetesObesityHartnup diseaseNonalcoholic steatohepatitisUrea cycle disorder
05

Safety considerations

Hartnup disease-like symptoms (pellagra-like skin rash, cerebellar ataxia, psychiatric symptoms)Aminoaciduria (excessive loss of neutral amino acids in urine)Malabsorption of essential amino acidsNutritional deficiencies (particularly tryptophan and niacin deficiency)
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Urinary phenylalanine excretionPlasma phenylalanine levelsUrinary neutral amino acidsEstimated glomerular filtration rate (eGFR)Serum FGF21 levelsGLP-1 levels

Beyond the preview

Go deeper on Sodium-dependent neutral amino acid transporter B0AT1 (B0AT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sodium-dependent neutral amino acid transporter B0AT1 (B0AT1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call